NeuroBo Pharmaceuticals Inc. (NRBO) Financial Statements (2024 and earlier)

Company Profile

Business Address 545 CONCORD AVENUE
CAMBRIDGE, MA 02138
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments22,435,00033,364,00016,387,00010,089,00013,908,00018,954,000
Cash and cash equivalents22,435,00033,364,00016,387,00010,089,00013,908,00018,954,000
Restricted cash and investments     15,000 
Receivables      
Prepaid expense  168,000197,000546,000153,000715,000
Other current assets64,000  48,00042,00017,000
Other undisclosed current assets13,000     
Total current assets:22,512,00033,532,00016,584,00010,683,00014,118,00019,686,000
Noncurrent Assets
Operating lease, right-of-use asset202,000 105,000130,000 
Property, plant and equipment46,0002,000110,000155,000200,000 
Deposits noncurrent assets      8,000
Other noncurrent assets21,000     
Other undisclosed noncurrent assets     150,000 
Total noncurrent assets:269,0002,000215,000285,000350,0008,000
TOTAL ASSETS:22,781,00033,534,00016,799,00010,968,00014,468,00019,694,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,235,000988,0002,131,0003,671,0002,060,0002,482,000
Accounts payable821,000708,000830,0002,575,000638,0002,044,000
Accrued liabilities4,414,000280,0001,301,0001,096,0001,422,000438,000
Debt      9,437,000
Financial instruments subject to mandatory redemption, settlement terms, share value, amount658,00010,796,000    
Other undisclosed current liabilities67,000 26,00024,00022,000 
Total current liabilities:5,960,00011,784,0002,157,0003,695,0002,082,00011,919,000
Noncurrent Liabilities
Long-term debt and lease obligation:   45,00070,000  
Liabilities, other than long-term debt136,000    1,000
Other liabilities      1,000
Operating lease, liability136,000 45,00070,000 
Other undisclosed noncurrent liabilities   (45,000)(70,000)94,000 
Total noncurrent liabilities:136,000 45,00070,00094,0001,000
Total liabilities:6,096,00011,784,0002,202,0003,765,0002,176,00011,920,000
Equity
Equity, attributable to parent16,685,00021,750,00014,597,0007,203,00012,292,0007,774,000
Common stock5,00025,00027,00020,00016,00022,000
Additional paid in capital124,945,000117,520,00096,394,00073,713,00049,130,00091,863,000
Accumulated other comprehensive income   4,00014,00012,000 
Accumulated deficit(108,265,000)(95,795,000)(81,828,000)(66,544,000)(36,866,000)(84,111,000)
Total equity:16,685,00021,750,00014,597,0007,203,00012,292,0007,774,000
TOTAL LIABILITIES AND EQUITY:22,781,00033,534,00016,799,00010,968,00014,468,00019,694,000

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Cost of goods and services sold     (227,000,000) 
Financing interest expense  (2,191,000)    
Gross profit:  (2,191,000)  (227,000,000) 
Operating expenses(15,886,000)(19,628,000)(15,298,000)(29,716,000)(20,176,000)(22,805,000)
Other undisclosed operating income  2,191,000  227,000,000 
Operating loss:(15,886,000)(19,628,000)(15,298,000)(29,716,000)(20,176,000)(22,805,000)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
3,416,0005,661,000 (1,000) (178,000)
Interest and debt expense     (1,114,000) 
Other undisclosed income from continuing operations before equity method investments, income taxes      
Loss from continuing operations before equity method investments, income taxes:(12,470,000)(13,967,000)(15,298,000)(29,717,000)(21,290,000)(22,983,000)
Other undisclosed income (loss) from continuing operations before income taxes  14,00039,000(22,000)(654,000)
Loss from continuing operations before income taxes:(12,470,000)(13,967,000)(15,284,000)(29,678,000)(21,312,000)(23,637,000)
Income tax expense (benefit) 3,248,000(26,331,000)4,013,00013,154,0007,179,000 
Other undisclosed income from continuing operations      
Loss from continuing operations:(9,222,000)(40,298,000)(11,271,000)(16,524,000)(14,133,000)(23,637,000)
Loss before gain (loss) on sale of properties:(11,271,000)(16,524,000)(14,133,000)(23,637,000)
Net loss:(9,222,000)(40,298,000)(11,271,000)(16,524,000)(14,133,000)(23,637,000)
Other undisclosed net income (loss) attributable to parent(3,248,000)26,331,000(4,013,000)(13,154,000)(7,179,000) 
Net loss available to common stockholders, diluted:(12,470,000)(13,967,000)(15,284,000)(29,678,000)(21,312,000)(23,637,000)

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(9,222,000)(40,298,000)(11,271,000)(16,524,000)(14,133,000)(23,637,000)
Comprehensive loss:(9,222,000)(40,298,000)(11,271,000)(16,524,000)(14,133,000)(23,637,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3,248,000)26,327,000(4,023,000)(13,152,000)(7,169,000) 
Comprehensive loss, net of tax, attributable to parent:(12,470,000)(13,971,000)(15,294,000)(29,676,000)(21,302,000)(23,637,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: